MicroRNA therapeutics for prostate cancer

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$282,967.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA137939-01A1
Award Id:
95857
Agency Tracking Number:
CA137939
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST, AUSTIN, TX, 78744
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
805509424
Principal Investigator:
ANDREASBADER
() -
ABADER@ASURAGEN.COM
Business Contact:
BERNARDANDRESS
() -
bandruss@mirnarx.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths in males, following only lung cancer. Despite advances leading to more efficient detection, a small but s ignificant number of patients present with advanced disease and/or disease that is hormone resistant or resistant to current therapeutics. Our proposal explores the novel application of small endogenous regulators of gene expression as a new class of thera peutics for prostate cancer. Within the last two decades there has been great interest in microRNAs (miRNAs), small, non-coding RNAs that have been initially identified as regulators of development, and have more recently been demonstrated to have a role i n a number of cancers. miRNAs appear to regulate the expression of genes associated with early development and cancer by blocking the translation of target mRNA genes. Their levels are significantly altered in tumors, and their role in regulating the expre ssion of key oncogenes and tumor suppressors suggests this differential expression may be involved in the pathophysiology of cancer. We hypothesize that dysregulated miRNAs are involved in maintaining cancer cell phenotypes and that correcting this dysregu lation -- either by miRNA replacement with mimetic or ablation with antisense molecules -- should reverse these phenotypes. The goal of this proposal is to investigate promising miRNAs, delivery methods and delivery molecules that are effective therapies i n animal models of human prostate cancer. We have substantial preliminary data that suggest a number of miRNAs may have therapeutic potential. In our investigations, we will test the therapeutic potential of miRNAs on several mouse models of human PrCa, in cluding a model that mimics invasiveness and metastasis. Additionally we will evaluate stabilizing and release compounds that will allow systemic delivery of miRNA therapeutics. We believe these studies will help establish potent anti-cancer miRNAs that ca n be stabilized and eventually targeted to tumors, allowing delivery of these molecules into the bloodstream. PUBLIC HEALTH RELEVANCE: Advanced prostate cancer continues to be the second leading cause of cancer deaths in males, and is often resista nt to conventional therapeutics. Our work may lead to the development of microRNA-based therapies that can be systemically administered and are highly and specifically active towards prostate cancer cells. This will result in a reduced incidence of death f rom prostate cancer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government